Healthcare / Medical Instruments & SuppliesTaiwan
$32.95
+0.10 (+0.30%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $41.9M · quality 49.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.3B
P/E
13.7x
↓EV/EBITDA
7.5x
↓ROE
9.8%
↑Gross Margin
35.6%
↓Debt/Equity
0.26
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.7%
FCF CAGR
-12.7%
FCF margin
8.5%
FCF / Net income
0.75x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.16B · net income $244.4M · FCF $183.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.16B | $2.16B | $2.20B | $2.15B | $1.94B |
| Net Income | $244.4M | $244.4M | $243.4M | $198.4M | $352.0M |
| EBITDA | $482.9M | $482.9M | $491.7M | $402.8M | $591.7M |
| EPS | — | — | 2.40 | 1.96 | 3.48 |
| Gross Margin | 35.6% | 35.6% | 34.0% | 35.1% | 35.8% |
| Operating Margin | 13.7% | 13.7% | 14.0% | 15.8% | 16.7% |
| Net Margin | 11.3% | 11.3% | 11.1% | 9.2% | 18.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.26 | 0.26 | 0.26 | 0.25 | 0.17 |
| Current Ratio | 1.40 | 1.40 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $183.0M | $183.0M | $-59.5M | $41.9M | $275.0M |
| Returns | |||||
| ROE | 9.8% | 9.8% | 10.1% | 8.3% | 14.6% |
| Valuation | |||||
| P/E | 13.67 | 13.67 | 17.15 | 26.89 | 17.33 |
| EV/EBITDA | 7.53 | 7.53 | 9.16 | 13.80 | 10.33 |
| P/B | 1.34 | 1.34 | 1.72 | 2.24 | 2.53 |
| Growth & Yield | |||||
| Revenue Growth | -1.7% | -1.7% | 2.3% | 10.8% | — |
| EPS Growth | — | — | 22.4% | -43.7% | — |
| Dividend Yield | 4.7% | 4.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-6.8%
Start / end P/E
n/dx → n/dx
EPS bridge
2.40 → n/d
Residual
-11.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.